

Richard L Schilsky

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9323739/richard-l-schilsky-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

161 papers	7,857 citations	38 h-index	87 g-index
172 ext. papers	9,703 ext. citations	5.8 avg, IF	5.83 L-index

#	Paper	IF	Citations
161	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1431-9	2.2	1245
160	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
159	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1631-1641	2.2	448
158	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2392-2401	27.4	434
157	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
156	Recommendations for management of patients with neuroendocrine liver metastases. <i>Lancet Oncology</i> , 2014 , 15, e8-21	21.7	315
155	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3817-25	2.2	286
154	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1277-80	2.2	273
153	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3737-3744	2.2	225
152	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019 , 25, 751-758	50.5	205
151	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3504-3504	2.2	193
150	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. <i>Journal of Clinical Oncology</i> , 2016 , 34, 179-85	2.2	165
149	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum	2.2	131
148	Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1775-81	2.2	127
147	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016 , 34, 987-1011	2.2	114
146	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	106
145	Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015 , 33, 786-809	2.2	91

144	Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. <i>JCO Oncology Practice</i> , 2020 , 16, 417-421	2.3	90
143	The evidence framework for precision cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 183-194	19.4	89
142	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2191-200	2.2	87
141	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1020-1044	2.2	83
140	Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2373-9	2.2	79
139	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1341-1367	2.2	75
138	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1242-1253	5	72
137	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019 , 37, 336-349	2.2	66
136	American Society of Clinical Oncology Statement: Biosimilars in Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1260-1265	2.2	65
135	Implementing personalized cancer care. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 432-8	19.4	63
134	The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. <i>Journal of Oncology Practice</i> , 2018 , 14, e412-e420	3.1	61
133	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3992-3999	2.2	60
132	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA3-LBA3	2.2	60
131	Modernizing Eligibility Criteria for Molecularly Driven Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2815-20	2.0	59
130	Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4553-7	2.2	58
129	Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	53
128	Prognostic factors for survival in patients treated in phase I clinical trials. <i>Cancer</i> , 1994 , 74, 1965-73	6.4	52
127	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1081	2.2	48

126	Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 582-7	2.2	45
125	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018 , 378, 2036-2044	59.2	41
124	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. <i>Journal of Clinical Oncology</i> , 2021 , 39, 155-169	2.2	38
123	Modulation of vinblastine resistance with cyclosporine: a phase I study. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 54, 421-9	6.1	37
122	Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. <i>Journal of the National Cancer Institute</i> , 1990 , 82, 1411-5	9.7	37
121	Closing the Rural Cancer Care Gap: Three Institutional Approaches. <i>JCO Oncology Practice</i> , 2020 , 16, 422-430	4.3	37
120	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. <i>Cancer</i> , 1989 , 63, 30-6	6.4	35
119	Development and use of integral assays in clinical trials. <i>Clinical Cancer Research</i> , 2012 , 18, 1540-6	12.9	34
118	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016 , 34, 3047-53	2.2	33
117	Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1521-30	2.2	33
116	Accelerating anticancer drug development - opportunities and trade-offs. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 777-786	19.4	32
115	Precision cancer medicine: the future is now, only better. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , 61-9	7.1	30
114	Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3725-30	2.2	30
113	Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. <i>Journal of the American College of Surgeons</i> , 2017 , 224, 1-7	4.4	27
112	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2443-2451	2.2	27
111	Randomized controlled trials and comparative effectiveness research. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4194-201	2.2	26
110	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020 , 6, 1461-1471	3.7	26
109	Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). <i>Journal of the National Cancer Institute</i> , 2015 , 107, 336	9.7	23

108	Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. <i>Investigational New Drugs</i> , 1999 , 17, 97-101	4.3	23
107	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1014-1014	2.2	23
106	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42, 84-7	3.5	22
105	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
104	Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	19
103	A concise history of the cancer and leukemia group B. <i>Clinical Cancer Research</i> , 2006 , 12, 3553s-5s	12.9	19
102	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 14139-52	3.3	19
101	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 132-132	2.2	18
100	Progress in Cancer Research, Prevention, and Care. <i>New England Journal of Medicine</i> , 2020 , 383, 897-900	59.2	18
99	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3872-3879	2.2	16
98	Publicly funded clinical trials and the future of cancer care. <i>Oncologist</i> , 2013 , 18, 232-8	5.7	16
97	Accrual to cancer clinical trials in the era of molecular medicine. <i>Science Translational Medicine</i> , 2011 , 3, 75cm9	17.5	16
96	Clinical Cancer Advances 2021: ASCOR Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1165-1184	2.2	16
95	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018 , 36, 617-623	2.2	16
94	Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. <i>JCO Precision Oncology</i> , 2020 , 4, 757-766	3.6	15
93	Commentary: tackling the challenges of developing targeted therapies for cancer. <i>Oncologist</i> , 2010 , 15, 484-7	5.7	14
92	Palbociclib in Patients With Pancreatic and Biliary Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	14
91	Circadian variation in plasma 5-fluorouracil concentrations during a 24-hour constant-rate infusion. <i>BMC Cancer</i> , 2015 , 15, 69	4.8	13

90	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019 , 37, 72-80	2.2	12
89	Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. <i>Cell</i> , 2017 , 171, 982-986	56.2	12
88	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 133-133	2.2	12
87	Status Update on Data Required to Build a Learning Health System. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1602-1607	2.2	11
86	Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. <i>Stem Cells</i> , 1996 , 14, 29-32	5.8	11
85	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. <i>Clinical Cancer Research</i> , 2021 , 27, 2394-2399	12.9	11
84	Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement 2018 , 6, 108		11
83	Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 484-9	4	10
82	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA108-LBA108	2.2	10
81	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020 , 15, 733-741	5	10
80	Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3203-3211	2.2	9
79	Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1690-1694	2.2	9
78	Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?. <i>JAMA Oncology</i> , 2018 , 4, 333-334	13.4	9
77	Integrating biomarkers in colorectal cancer trials in the West and China. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 553-60	19.4	9
76	Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. <i>Otolaryngology - Head and Neck Surgery</i> , 1988 , 98, 295-8	5.5	9
75	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020 , 15, 743-750	5	9
74	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021 , 148, 560-571	7.5	9
73	Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Recommendations. <i>Clinical Cancer Research</i> , 2021 , 27, 2430-2434	12.9	9

72	Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. <i>Oncologist</i> , 2019 , 24, 1287-1290	5.7	8
71	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 34, 509-14	3.5	8
70	Challenges and approaches to implementing master/basket trials in oncology. <i>Blood Advances</i> , 2019 , 3, 2237-2243	7.8	8
69	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 122-122	2.2	7
68	Wither the cooperative groups?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 251-4	2.2	6
67	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9041-9041	2.2	6
66	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4637-4637	2.2	6
65	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. <i>Clinical Cancer Research</i> , 2021 , 27, 2408-2415	12.9	6
64	Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. <i>Journal of Oncology Practice</i> , 2019 , 15, 575-583	3.1	5
63	Hans Christian Andersen and the Value of New Cancer Treatments. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 441-442	9.7	4
62	Moving from evaluation to value in cancer care. <i>Clinical Cancer Research</i> , 2015 , 21, 947-9	12.9	4
61	Drug approval challenges in the age of personalized cancer treatment. <i>Personalized Medicine</i> , 2011 , 8, 633-640	2.2	4
60	Clinical cardiotoxicity of esorubicin (4Rdeoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. <i>Investigational New Drugs</i> , 1990 , 8, 221-6	4.3	4
59	Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era. <i>Oncologist</i> , 1996 , 1, 244-247	5.7	4
58	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2021 , OP2100394	2.3	4
57	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5508-5508	2.2	4
56	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021 , 42, 2373-2383	3.5	4
55	Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. <i>JCO Oncology Practice</i> , 2020 , 16, e977-e990	2.3	3

54	Access versus evidence: The regulators dilemma. <i>Clinical Trials</i> , 2018 , 15, 240-242	2.2	3
53	How not to treat cancer. <i>Lancet Oncology</i> , 2008 , 9, 504-5	21.7	3
52	Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 455-455	2.2	3
51	Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11520-11520	2.2	3
50	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2532	2.2	3
49	Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 638-638	2.2	3
48	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 480-487	2.2	3
47	Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies-a WINning strategy?. <i>Ecancermedicalscience</i> , 2015 , 9, 564	2.7	2
46	Phase I and II clinical trial design for targeted agents. <i>Targeted Oncology</i> , 2006 , 1, 220-227	5	2
45	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 107-107	2.2	2
44	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5567-5567	2.2	2
43	Governance of a Learning Health Care System for Oncology: Patient Recommendations. <i>JCO Oncology Practice</i> , 2021 , 17, e479-e489	2.3	2
42	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021 , 5, 33	9.8	2
41	Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11565-11565	2.2	2
40	Creating a Learning Health Care System in Oncology 2016 , 3-21		2
39	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-10	3.6	2
38	A New Look at the State of Cancer Care in America. <i>Journal of Oncology Practice</i> , 2018 , 14, 397-399	3.1	2
37	The National Clinical Trials Network and the cooperative groups: The road not taken. <i>Cancer</i> , 2020 , 126, 5008-5013	6.4	1

36	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
35	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 106-106	2.2	1
34	Developing a virtual collaborative to facilitate palliative care and quality improvement learning in oncology.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 252-252	2.2	1
33	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18290-e18290	2.2	1
32	Biosimilar usage in practices within the ASCO PracticeNET learning network.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 77-77	2.2	1
31	Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. <i>Oncologist</i> , 2020 , 25, e405-e411	5.7	1
30	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020 , 3, e2014661	10.4	1
29	Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6043-6043	2.2	1
28	Strategic development of precision cancer medicine in the United States. <i>Molecular Oncology</i> , 2021 , 15, 1747-1749	7.9	1
27	Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation sequencing. <i>Ecancermedicalscience</i> , 2016 , 10, 669	2.7	1
26	Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. <i>JCO Oncology Practice</i> , 2021 , 17, 41-51	2.3	1
25	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6531-6531	2.2	0
24	Reply to L. Casadaban et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1373-1374	2.2	
23	Reply to M. Hutton-Potts and A.M. Joshua. <i>JCO Oncology Practice</i> , 2020 , 16, 285-286	2.3	
22	Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1134	2.2	
21	Response. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djw001	9.7	
20	Using Big Data to Track Trends in Medical Practice. <i>Journal of Oncology Practice</i> , 2015 , 11, 69-70	3.1	
19	Reply to F.E. Vera-Badillo et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3198	2.2	

- 18 Reply to L.k. Griffeth et al and J.E. Battley et al. *Journal of Clinical Oncology*, **2014**, 32, 2812-3 2.2
- 17 Update in hematology and oncology: evidence published in 2010. *Annals of Internal Medicine*, **2011**, 154, 487-94 8
- 16 Patient Experiences, Trust, and Preferences for Health Data Sharing. *JCO Oncology Practice*, **2021**, OP2100491
- 15 Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.. *Journal of Clinical Oncology*, **2018**, 36, 6529-6529 2.2
- 14 Hypertension and use of bevacizumab among patients treated in community settings.. *Journal of Clinical Oncology*, **2019**, 37, e18279-e18279 2.2
- 13 Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation. *Ecancermedalscience*, **2013**, 7, 344 2.7
- 12 Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.. *Journal of Clinical Oncology*, **2014**, 32, 11047-11047 2.2
- 11 Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials.. *Journal of Clinical Oncology*, **2015**, 33, 11097-11097 2.2
- 10 Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. *Journal of Clinical Oncology*, **2015**, 33, 3585-3585 2.2
- 9 Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2015**, 33, 7524-7524 2.2
- 8 A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.. *Journal of Clinical Oncology*, **2013**, 31, 2570-2570 2.2
- 7 Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. *Journal of Clinical Oncology*, **2013**, 31, 237-237 2.2
- 6 Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.. *Journal of Clinical Oncology*, **2021**, 39, 6509-6509 2.2
- 5 Reply to S.D. Lucio. *Journal of Clinical Oncology*, **2018**, 36, 2127 2.2
- 4 Scarcity of vital oncology drugs: finding long-term solutions. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 597-9 0.6
- 3 Targeted therapy for cancer: asking the right questions. *Oncology*, **2012**, 26, 947-9 1.8
- 2 ASCO® initiative to define value in cancer care. *American Journal of Managed Care*, **2014**, 20, E1 2.1
- 1 Advanced clinical trials for China. *Chinese Clinical Oncology*, **2012**, 1, 3 2.3

